AKS-544d

AKS-544d is a long-acting, once-weekly insulin therapy specifically designed for the treatment of diabetes mellitus in dogs. Developed by Akston Biosciences, it is a recombinant fusion protein consisting of canine insulin fused to a canine Fc fragment. This design utilizes the neonatal Fc receptor (FcRn) salvage pathway to significantly extend the half-life of the insulin in the canine bloodstream, allowing for once-weekly subcutaneous administration compared to the standard twice-daily injections required with conventional insulins. The primary goal of AKS-544d is to improve glycemic control and quality of life for diabetic dogs and their owners by reducing the frequency of administration and the associated stress of frequent injections.

Other names

canine insulin Fc-fusion protein